Barron's Streetwise New Weight Loss Pill. Plus, Congress and the Disappearing $4 Trillion.
Apr 25, 2025
Discover the breakthrough of orforglipron, a new oral weight loss pill that's changing the game in obesity treatment. Dive into the soaring stock performance of pharmaceutical companies and the quirky ties between drug markets and federal budgeting. Unpack the growing federal debt, projected to skyrocket, and explore the implications of tax legislation like the Tax Cuts and Jobs Act. Plus, enjoy a lighter moment as personal anecdotes add humor to the serious discussion about fiscal responsibility.
AI Snips
Chapters
Transcript
Episode notes
Orforglipron: Promising Oral Obesity Pill
- Eli Lilly's new oral obesity pill, orforglipron, shows weight loss comparable to injectables.
- Side effects like diarrhea and nausea are common but lead to low discontinuation, promising wide usability.
Small Molecule Pill Advantages
- Lilly's orforglipron is a small molecule pill, easier to manufacture and less digested than peptide pills.
- This enables oral drugs to potentially match injectable drugs' effectiveness for diabetes and obesity.
Bat Box Struggles
- Jack shares his personal struggle attracting bats to his new bat boxes.
- Despite thoughtful efforts, the bats refuse to move in, illustrating unpredictable nature of wildlife.